natgillin/translations-raw huggingface dataset:
Det kan overvejes at anvende cholsyre under amning, hvis lægen finder, at fordelene for patienten overstiger den mulige risiko. 
Cholic acid can be used during breastfeeding if the doctor considers that the benefits to the patient outweigh the possible risk.
50 mg kapslerne er orange (sort aftryk "ASK001" og "50 mg"). 
The 50 mg capsules are orange (black imprint “ASK001” and “50mg”).
Heraf var 22 (42 %) behandlingsnaive, dvs. de fik deres første dosis cholsyre i undersøgelse CAC-002-01. 
A total of 53 patients took part in the clinical study and received at least one dose of cholic acid; 22 (42%) were treatment naive, i.e., received their first dose of cholic acid during study CAC002-01.
Hvis du har taget for meget Kolbam 
If you take more Kolbam than you should
<{DD måned ÅÅÅÅ}> 
DD month YYYY
Tabellen indeholder desuden bivirkninger, der beskrives i litteraturen, og hvis hyppighed ikke er kendt: 
The adverse reactions reported in the literature with an unknown frequency are also reported in the following table.
Kolbam anvendes til behandling af disse medfødte fejl i galdesyresyntesen. 
Kolbam is used to treat these ‘inborn errors of bile acid synthesis'.
Titaniumdioxid (E171) Jernoxid, rød (E172) 
Titanium dioxide (E171) Red iron oxide (E172)
MARKEDSFØRINGSTILLADELSESNUMMER) EU/1/13/895/001 
MARKETING AUTHORISATION NUMBER EU/1/13/895/001
Til patienter med familiær hypertriglyceridæmi skal dosis af cholsyre fastlægges og om nødvendigt tilpasses, idet dosisforhøjelse kan være nødvendig for at undertrykke galdesyrer i urinen (se pkt. 
The cholic acid dose for patients with familial hypertriglyceridaemia will have to be established and adjusted as necessary: an elevated dose may be required in order to suppress urinary bile acids (see section 4.4).
Patienter med nydiagnosticeret hypertriglyceridæmi eller med familiær hypertriglyceridæmi kan have nedsat cholsyreabsorption fra tarmen. 
Patients with newly diagnosed, or a family history of, familial hypertriglyceridaemia may have poor absorption of cholic acid from the intestine.
• østrogen 
• oestrogen,
- Hvis du får bivirkninger, skal du sige det til lægen eller på apoteket eller til sundhedspersonalet. 
- If you get any side effects, talk to your doctor, pharmacist or nurse.
KVALITATIV OG KVANTITATIV SAMMENSÆTNING Hver hård kapsel indeholder 250 mg cholsyre. 
QUALITATIVE AND QUANTITATIVE COMPOSITION Each hard capsule contains 250 mg of cholic acid.
Hvis administration af ciclosporin anses for nødvendig, bør galdesyreindholdet overvåges tæt, og dosis af cholsyre justeres i henhold hertil. 
If administration of ciclosporin is considered necessary, serum and urinary bile acid levels should be closely monitored and the cholic acid dose adjusted accordingly.
KVALITATIV OG KVANTITATIV SAMMENSÆTNING Hver hård kapsel indeholder 50 mg cholsyre. 
QUALITATIVE AND QUANTITATIVE COMPOSITION Each hard capsule contains 50 mg of cholic acid.
Denne indlægsseddel blev senest revideret DDmÅÅÅÅ. 
This leaflet was last revised in DDmonthYYYY.
Indehaver af markedsføringstilladelsen Retrophin Europe Limited Palmerston House, Fenian Street Dublin 2 
Marketing Authorisation Holder Retrophin Europe Limited Palmerston House Fenian Street
Kolbam, 250 mg: Hver kapsel indeholder 250 mg cholsyre. 
Kolbam 250 mg: Each capsule contains 250 mg of cholic acid.
Registret skal overvåge akkumulerende data om sikkerheden og virkningen til behandling af medfødte fejl i galdesyresyntesen hos spædbørn, børn, unge og voksne som følge af sterol 27-hydroxylase (manifesteret som cerebrotendinøs xanthomatose, CTX), 2- (eller α-) methylacyl-CoA racemase (AMACR) og kolesterol 7α-hydroxylase (CYP7A1) mangel. 
The registry will monitor accumulating data on efficacy and safety in the treatment of inborn errors in primary bile acid synthesis in infants, children, adolescents and adults due to Sterol 27-hydroxylase (presenting as cerebrotendinous xanthomatosis,
Eksogen cholsyre vil efter absorption indgå i kroppens pool af galdesyrer og gennemløbe en række cyklusser i det enterohepatiske kredsløb. 
Once absorbed, exogenous cholic acid will enter into the body's bile acid pool and will undergo multiple cycles of enterohepatic circulation.
Kolbam, 50 mg: Hver kapsel indeholder 50 mg cholsyre. 
Kolbam 50 mg: Each capsule contains 50 mg of cholic acid.
250 mg kapslerne er hvide (sort aftryk "ASK002" og "250 mg"). 
The 250 mg capsules are white (black imprint “ASK002” and “250mg”).
Propylenglycol (E1520) Salmiakspiritus (E527) Kaliumhydroxid (E525) Sort jernoxid (E172) 
Propylene Glycol (E1520) Strong Ammonia Solution (E527) Potassium Hydroxide (E525) Black Iron Oxide (E172)
Ved familiær hypertriglyceridæmi skal dosis af cholsyre fastlægges og tilpasses efter behov (se pkt. 
The cholic acid dose for patients with familial triglyceridaemia will have to be established and adjusted as necessary (see section 4.2).
Niveauet af galdesyrer i urinen var normalt hos alle patienter (100 %) ved baseline og ved dårligste vurderinger efter baseline, og hos de fleste patienter (88 %) ved den bedste vurdering efter baseline. 
Urinary bile acids were normal for all patients (100%) at baseline and worst post-baseline assessments, and for most patients (88%) at the best post-baseline assessment; 1 patient (12%) had a slight elevation of urinary bile acids at best post-baseline assessment.
Undersøgelsen var åben og urandomiseret og havde én forsøgsarm. 
The study was an open-label, single arm, non-randomized design.
• hudforandringer 
• skin lesions
• let kvalme 
Hepatic impairment
Pædiatrisk population cholsyre sikkerhed og virkning hos nyfødte børn (under 1 måned) er ikke klarlagt. 
The safety and efficacy of cholic acid in neonates less than one month of age has not been established.
Hvis du er gravid, kan det overvejes at anvende cholsyre, hvis lægen finder, at fordelene for dig overstiger den mulige risiko. 
The use of cholic acid may be considered during pregnancy if your doctor considers that the benefits to you outweigh any possible risk.
Kolbam, hårde kapsler, 50 mg Kolbam, hårde kapsler, 250 mg cholsyre 
Kolbam 50 mg hard capsules Kolbam 250 mg hard capsules cholic acid
250 mg kapsel 
250 mg Capsule shell Gelatin
Patienter med sygdomme med medfødte fejl i galdesyntesen kan ikke danne cholsyre og galde på normal måde. 
Patients with certain types of conditions known as inborn errors of bile synthesis cannot produce cholic acid and bile normally, which leads to the production and build-up of abnormal substances that are potentially damaging to the liver.
250 mg kapsel: Kapselstørrelse 0 med hvid overdel og hvid underdel (sort aftryk "ASK002" og "250 mg"). 
250 mg capsule: Size number 0 capsule with a white cap (black imprint “ASK002”) and white body (black imprint “250mg”).
• halsbrand (ved tilbageløb fra mavesækken) 
• heartburn (gastric reflux)
LÆGEMIDLETS NAVN Kolbam, hårde kapsler, 250 mg. 
NAME OF THE MEDICINAL PRODUCT Kolbam 250 mg hard capsules.
Behandling med cholsyre medfører sædvanligvis kun lette til moderate bivirkninger hos både voksne og børn; nedenstående tabel angiver de vigtigste iagttagne bivirkninger. 
Adverse reactions in patients (both adults and children) receiving cholic acid are generally mild to moderate in severity; the main reactions observed are given in the table below.
LÆGEMIDLETS NAVN Kolbam, hårde kapsler, 50 mg. 
NAME OF THE MEDICINAL PRODUCT Kolbam 50 mg hard capsules.
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver kapsel indeholder 250 mg cholsyre 
STATEMENT OF ACTIVE SUBSTANCE(S) Each capsule contains 250 mg cholic acid
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver kapsel indeholder 50 mg cholsyre 
STATEMENT OF ACTIVE SUBSTANCE(S) Each capsule contains 50 mg cholic acid
50 mg kapsel: Kapselstørrelse 2 med orange overdel og underdel (sort aftryk "ASK001" og "50 mg"). 
50 mg capsule: Size number 2 capsule with a Swedish orange cap (black imprint “ASK001”) and body (black imprint “50mg”).
Printerblæk - Shellac (E904) - Propylenglycol (E1520) - Salmiakspiritus (E527) - Kaliumhydroxid (E525) - Sort jernoxid (E172) 
Printing ink Shellac (E904) Propylene Glycol (E1520) Strong Ammonia Solution (E527) Potassium Hydroxide (E525) Black Iron Oxide (E172) What Kolbam looks like and contents of the pack Kolbam is provided as hard capsules.
Ved klare tegn på svært leversvigt bør behandlingen seponeres tidligere. 
Treatment should be stopped earlier if there are clear indicators of severe hepatic failure.
Cholsyre har sædvanligvis kun lette til moderate bivirkninger hos både voksne og børn, som det fremgår af følgende tabel, der bygger på de kliniske undersøgelser. 
Based on clinical trial data, adverse reactions in patients (both adults and children) receiving cholic acid are generally mild to moderate in severity and are provided in the following table.
- Spørg lægen, apotekspersonalet eller sundhedspersonalet, hvis der er mere, du vil vide. 
You should check with your doctor or pharmacist if you are unsure.
Hyppighed 
Malaise
Kolbam, hårde kapsler, 50 mg cholsyre 
NAME OF THE MEDICINAL PRODUCT Kolbam 50 mg hard capsules cholic acid
Kolbam, hårde kapsler, 250 mg cholsyre 
NAME OF THE MEDICINAL PRODUCT Kolbam 250 mg hard capsules cholic acid
Dosering 
Breastfeeding
Emballage Indhold Pakningsstør relse 
Packaging Content (concentration)
Indgivelse svej 
Route of administration
Denne dosis må ikke øges. 
This dose should not be increased.
Dato for første markedsføringstilladelse: 4. marts 2011 Dato for seneste fornyelse: 19. november 2015 
Date of first authorisation: 04 March 2011 Date of latest renewal: 19 November 2015
Prøv at tage medicinen på nogenlunde samme tidspunkt hver dag. 
Try to take your daily dose at about the same time each day.
Ifirmacombi bør tages mindst en time før eller fire timer efter disse lægemidler. 
Ifirmacombi should be taken at least one hour before or four hours after these medications;
Primær aldosteronisme: 
Primary aldosteronism:
Ikke kendt: tinnitus 
Not known: tinnitus
og 5.1). 
and 5.1)
Se også information under overskriften ”Tag ikke Ifirmacombi”. 
See also information under the heading “Do not take Ifirmacombi”.
Den maksimale blodtrykssænkende virkning nås 6-8 uger efter behandlingen er påbegyndt. 
The maximal blood pressure lowering effect should be reached 6-8 weeks after beginning treatment.
Børn og unge Ifirmacombi må ikke gives til børn og unge (under 18 år). 
Children and adolescents Ifirmacombi should not be given to children and adolescents (under 18 years).
Yderligere information om interaktioner med irbesartan: 
Additional information on irbesartan interactions:
Nogle af bivirkningerne kan dog være alvorlige og kræve behandling. 
Some of these effects may be serious and may require medical attention.
Selvom dette ikke er dokumenteret for Ifirmacombi, kan der forventes en lignende virkning. 
While this is not documented with Ifirmacombi, a similar effect should be anticipated.
Efter enten oral eller intravenøs administration af 
After either oral or intravenous administration of
Du kan tage Ifirmacombi med eller uden mad. 
You can take Ifirmacombi with or without food.
Non-steroide antiinflammatoriske lægemidler: 
Non-steroidal anti-inflammatory drugs:
Det er vigtigt, at du fortsætter med at tage Ifirmacombi, indtil lægen siger, du kan stoppe. 
It is important that you continue to take Ifirmacombi until your doctor tells you otherwise.
Chloridmangel er generelt beskeden og kræver normalt ingen behandling. 
Chloride deficit is generally mild and usually does not require treatment.
Ikke kendt: feber 
Not known: fever
I langvarige opfølgningsstudier blev virkningen af irbesartan/hydrochlorthiazid opretholdt i mere end 1 år. 
In long-term follow-up studies, the effect of irbesartan/hydrochlorothiazide was maintained for over one year.
Hvis det er klinisk hensigtsmæssigt, kan direkte skift fra monoterapi til de faste kombinationer overvejes: 
When clinically appropriate direct change from monotherapy to the fixed combinations may be considered:
Ikke kendt: postural hypotension 
Not known: postural hypotension
Brug af Ifirmacombi sammen med mad, drikke og alkohol Ifirmacombi kan tages med eller uden mad. 
Ifirmacombi with food, drink and alcohol Ifirmacombi can be taken with or without food.
De almindelige tegn og symptomer på overdosering er kvalme og døsighed. 
The most common signs and symptoms of overdose are nausea and somnolence.
Ifirmacombi frarådes til behandling af børn og unge, da sikkerhed og virkning ikke er klarlagt. 
Ifirmacombi is not recommended for use in children and adolescents because the safety and efficacy have not been established.
Se punkt 2 ”Ifirmacombi indeholder natrium”. 
See section 2 "Ifirmacombi contains sodium".
Det primære formål med forsøget var at sammenligne andelen af patienter, hvis SeDBT var kontrolleret (SeDBT < 90 mmHg) efter 5 ugers behandling. 
The primary objective of this study was to compare the proportion of patients whose SeDBP was controlled (SeDBP < 90 mmHg) at Week 5 of treatment.
Irbesartans plasma-proteinbinding er ca. 96%, med en ubetydelig binding til cellulære blodkomponenter. 
Plasma protein binding of irbesartan is approximately 96%, with negligible binding to cellular blood components.
Hvis Ifirmacombi anvendes i ammeperioden, bør dosis være så lav som muligt. 
If Ifirmacombi is used during breast feeding, doses should be kept as low as possible.
Hyppigheden af bivirkninger anført nedenfor defineres i henhold til følgende konventioner: meget almindelig (≥ 1/10); almindelig (≥ 1/100 til < 1/10); ikke almindelig (≥ 1/1.000 til < 1/100); sjælden (≥ 1/10.000 til < 1/1.000); meget sjælden (< 1/10.000) ikke kendt (kan ikke estimeres ud fra forhåndenværende data) 
The frequency of adverse reactions listed below is defined using the following convention: - Very common (1/10) - Common (1/100 to <1/10) - Uncommon (1/1,000 to <1/100) - Rare (1/10,000 to <1/1,000) - Very rare (<1/10,000) - Not known (cannot be estimated from the available data)
Metabolisk og endokrin virkning: 
Metabolic and endocrine effects:
Ifirmacombi er kun sjældent blevet associeret med symptomatisk hypotension hos hypertensive patienter uden andre risikofaktorer for hypotension. 
Ifirmacombi has been rarely associated with symptomatic hypotension in hypertensive patients without other risk factors for hypotension.
Hvis du har glemt at tage Ifirmacombi 
If you forget to take Ifirmacombi
Ikke almindelig: seksuel dysfunktion, ændret libido 
Uncommon: sexual dysfunction, libido changes
Epidemiologiske studier har vist, at langtidsbehandling med hydrochlorthiazid reducerer risikoen for kardiovaskulær mortalitet og morbiditet. 
Epidemiological studies have shown that long term treatment with hydrochlorothiazide reduces the risk of cardiovascular mortality and morbidity.
Den vigtigste cirkulerende metabolit er glukuronidet af irbesartan (ca. 6%). 
The major circulating metabolite is irbesartan glucuronide (approximately 6%).
Renal arteriestenose - renovaskulær hypertension: 
Renal artery stenosis - Renovascular hypertension:
12% af patienterne var diabetikere, 34% var hyperlipidæmiske, og den hyppigste kardiovaskulære sygdom var stabil angina pectoris hos 3,5% af deltagerne. 
Twelve percent (12%) of patients were diabetic, 34% were hyperlipidemic and the most frequent cardiovascular condition was stable angina pectoris in 3.5% of the participants.
Der var ingen tegn på mutagenicitet, klastogenicitet eller karcinogenecitet. 
There was no evidence of mutagenicity, clastogenicity or carcinogenicity.
Angiotensin II-receptorantagonister (AIIRAer): 
Angiotensin II Receptor Antagonists (AIIRAs):
Du skal stoppe behandlingen med Ifirmacombiog søge lægehjælp. 
You should discontinue Ifirmacombi treatment and seek medical attention.
Potentiel toksicitet af irbesartan/hydrochlorthiazid-kombinationen efter oral administration blev undersøgt hos rotter og makakaber i studier af op til 6 måneders varighed. 
The potential toxicity of the irbesartan/hydrochlorothiazide combination after oral administration was evaluated in rats and macaques in studies lasting up to 6 months.
Der findes ingen kontrollerede epidemiologiske data vedrørende risikoen med angiotensin-II-receptorantagonister (AIIRA'ere), men lignende risici kan findes for denne lægemiddelgruppe. 
Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks may exist for this class of drugs.
Ved bilkørsel eller betjening af maskiner skal der tages hensyn til, at der kan opstå svimmelhed eller træthed under behandling af hypertension. 
When driving vehicles or operating machines, it should be taken into account that occasionally dizziness or weariness may occur during treatment of hypertension.
Gulsot hepatitis, abnorm leverfunktion 
jaundice hepatitis, abnormal liver function
Fødeindtagelse påvirker ikke biotilgængeligheden af Ifirmacombi. 
Food does not affect the bioavailability of Ifirmacombi.
Der foreligger ikke specifikke oplysninger om behandling af overdosering med Ifirmacombi. 
No specific information is available on the treatment of overdose with Ifirmacombi.
Hvis nogen af disse bivirkninger medfører problemer for dig, skal du kontakte lægen. 
If any of these side effects causes you problems, talk to your doctor.
Desuden var øget blodurinstof (BUN) (2,3%), kreatinkinase (1,7%) og kreatinin (1,1%) også almindelige observationer i forsøgene. 
In addition increases in blood urea nitrogen (BUN) (2.3%), creatine kinase (1.7%) and creatinine (1.1%) were also commonly observed in the trials.
Irbesartan er en potent, oral aktiv, selektiv angiotensin II-receptor (AT1 undergruppe) antagonist. 
Irbesartan is a potent, orally active, selective angiotensin-II receptor (AT1 subtype) antagonist.
Typen og forekomsten af de bivirkninger, der er indberettet hos patienter, som har fået behandling med kombinationen, svarede til bivirkningsprofilen for patienter i enkeltstofbehandling. 
The types and incidences of adverse events reported for patients treated with the combination were similar to the adverse event profile for patients on monotherapy.
Markant hyperkalcæmi kan være tegn på skjult hyperparathyreoidisme. 
Marked hypercalcaemia may be evidence of hidden hyperparathyroidism.
C irbesartan kan 80-85% af den cirkulerende radioaktivitet i plasma tilskrives uomdannet irbesartan. 
C irbesartan, 80-85% of the circulating plasma radioactivity is attributable to unchanged irbesartan.
Almindelig: træthed 
Common: fatigue
Hos kaniner sås abort eller tidlig resorption ved doser, som forårsagede signifikant maternel toksicitet, inklusive mortalitet. 
abortion or early resorption was noted at doses causing significant maternal toxicity, including mortality.
Kortikosteroider, ACTH: elektrolytdepletering, specielt hypokaliæmi, kan forstærkes; 
Corticosteroids, ACTH: electrolyte depletion, particularly hypokalaemia, may be increased;
Hvis du ønsker yderligere oplysninger om Ifirmacombi, skal du henvende dig til den lokale repræsentant for indehaveren af markedsføringstilladelsen: 
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Virkningen af Ifirmacombi afhænger ikke af alder eller køn. 
There is no difference in response to Ifirmacombi, regardless of age or gender.
C irbesartan genfindes ca. 20% radioaktivitet i urinen og resten i afføringen. 
C irbesartan, about 20% of the radioactivity is recovered in the urine, and the remainder in the faeces.
Non-steroide antiinflammatoriske lægemidler: administration af et non-steroidt antiinflammatorisk lægemiddel kan reducere den diuretiske, natriuretiske og antihypertensive virkning af thiaziddiuretika hos nogle patienter. 
Non-steroidal anti-inflammatory drugs: the administration of a non-steroidal anti-inflammatory drug may reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics in some patients;
Ikke kendt:thrombocytopeni 
Not known: thrombocytopenia
Yderligere information om de individuelle stoffer: Udover ovenfor nævnte bivirkninger for kombinationspræparatet, kan andre tidligere rapporterede bivirkninger i forbindelse med ét af enkeltkomponenterne være potentielle bivirkninger ved Ifirmacombi. 
Additional information on individual components: in addition to the adverse reactions listed above for the combination product, other adverse reactions previously reported with one of the individual components may be potential adverse reactions with Ifirmacombi.
Der er rapporteret eksacerbation eller provokation af systemisk lupus erythematosus ved brug af thiaziddiuretika. 
Exacerbation or activation of systemic lupus erythematosus has been reported with the use of thiazide diuretics.
Irbesartan metaboliseres hovedsageligt af CYP2C9 og i mindre udstrækning ved glukuronidering. 
Irbesartan is mainly metabolised by CYP2C9 and to a lesser extent by glucuronidation.
Ved oral administration af Ifirmacombi er den absolutte orale biotilgængelighed 60-80% for irbesartan og 50-80% for hydrochlorthiazid. 
Following oral administration of Ifirmacombi, the absolute oral bioavailability is 6080% and 50-80% for irbesartan and hydrochlorothiazide, respectively.
Farmakoterapeutisk klassifikation: angiotensin-II-antagonister og diuretika, ATC-kode: C09DA04. 
Pharmacotherapeutic group: angiotensin II antagonists and diuretics, ATC code: C09DA04.
Sådanne tilstande skal korrigeres inden initiering af behandling med Ifirmacombi. 
Such conditions should be corrected before initiating therapy with Ifirmacombi.
Tag altid lægemidletnøjagtigt efter lægens anvisning. 
Always take this medicine exactly as your doctor has told you.
Filmovertræk: Polyvinylalcohol 
Polyvinyl alcohol
Din læge vil normalt anbefale, at du stopper med at tage Ifirmacombi, inden du bliver gravid, eller så snart du ved, at du er gravid. 
Your doctor will normally advise you to stop taking Ifirmacombi before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Ifirmacombi.
Effekten af irbesartan/hydrochlorthiazid på fertilitet er ikke evalueret i dyrestudier, da der ikke har været tegn på skadelig virkning på fertiliteten hos dyr eller mennesker af hverken irbesartan eller hydrochlorthiazid, når de administreres alene. 
The effects of the irbesartan/hydrochlorothiazide combination on fertility have not been evaluated in animal studies, as there is no evidence of adverse effect on fertility in animals or humans with either irbesartan or hydrochlorothiazide when administered alone.
Hvis det er nødvendigt at genoptage diuretikabehandlingen, anbefales det at beskytte udsatte områder mod sollys eller kunstige UVA-stråler. 
If a re-administration of the diuretic is deemed necessary, it is recommended to protect exposed areas to the sun or to artificial UVA.
Hvis denne dosis ikke kan nedsætte dit blodtryk som ønsket, vil lægen ordinere yderligere behandling til dig. 
If this medicine does not help to reduce your blood pressure as required, the doctor will prescribe additional treatment to you.
Ifirmacombi indeholder hydrochlorthiazid og kan derfor ikke anbefales under graviditetens første trimester. 
Since Ifirmacombi contains hydrochlorothiazide, it is not recommended during the first trimester of pregnancy.
Ifirmacombi påvirker sandsynligvis ikke din evne til at køre bil eller betjene maskiner. 
Ifirmacombi is unlikely to affect your ability to drive or use machines.
Ikke kendt: åndenød (inklusive pneumoni og lungødem) 
Not known: respiratory distress (including pneumonitis and pulmonary oedema)
Lægen vil forklare, hvordan du skifter fra den tidligere behandling til behandling med Ifirmacombi. 
Your doctor will instruct you how to switch from the previous treatment to Ifirmacombi.
Den selektive antagonisme mod angiotensin-II (AT1)-receptorerne resulterer i en forhøjelse af renin- og angiotensin-II-niveauerne i plasma og i nedsat aldosteronkoncentration i plasma. 
The selective antagonism of the angiotensin-II (AT1) receptors results in increases in plasma renin levels and angiotensin-II levels, and a decrease in plasma aldosterone concentration.
Hvis du får et eller flere af disse symptomer eller får åndenød, skal du holde op med at tage Ifirmacombi og straks søge lægehjælp. 
If you get any of the above symptoms or get short of breath, stop taking Ifirmacombi and contact your doctor immediately.